AR041206A1 - Imidazolpiridinas y metodos para preparar y usarlas - Google Patents

Imidazolpiridinas y metodos para preparar y usarlas

Info

Publication number
AR041206A1
AR041206A1 ARP030103249A ARP030103249A AR041206A1 AR 041206 A1 AR041206 A1 AR 041206A1 AR P030103249 A ARP030103249 A AR P030103249A AR P030103249 A ARP030103249 A AR P030103249A AR 041206 A1 AR041206 A1 AR 041206A1
Authority
AR
Argentina
Prior art keywords
heterocycloalkyl
cycloalkyl
alkyl
heteroaryl
alkoxy
Prior art date
Application number
ARP030103249A
Other languages
English (en)
Original Assignee
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc
Publication of AR041206A1 publication Critical patent/AR041206A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Abstract

Se presentan compuestos que poseen una alta afinidad por Alk5 y/o Alk4, y pueden ser útiles como antagonistas de los mismos para la prevención y/o tratamiento de numerosas enfermedades, incluyendo desórdenes fibróticos. Reivindicación 1: Uncompuesto de la siguiente fórmula (1) en donde cada uno de X1, X2, X3, y X4 es independientemente seleccionado de entre CRx o N; siempre que sólo dos de entre X1, X2, X3 y X4 puedan ser N de manera simultánea; cada de Y1 e Y2, es independientementeseleccionado de entre CRy o N; siempre que al menos uno de entre Y1 e Y2 sea N; cada R1 es independientemente seleccionado de entre alquilo, alquenilo, alquinilo, alcoxi, acilo, halo, hidroxi, amino, nitro, ciano, guanadino, amidino, carboxi, sulfo,mercapto, alquilsulfanilo, alquilsulfinilo, alquilsulfonilo, aminocarbonilo, alquilcarbonilamino, alquilsulfonilamino, alcoxicarbonilo, alquilcarboniloxi, urea, tiourea, sulfamoilo, sulfamida, carbamoilo, cicloalquilo, cicloalquiloxi,cicloalquilsulfanilo, heterocicloalquilo, heterocicloalquiloxi, heterocicloalquilsulfanilo, arilo, ariloxi, arilsulfanilo, aroil, heteroarilo, heteroariloxi, heteroarilsulfanilo, o heteroaroilo; cada R2 es independientemente seleccionado de entrealquilo, alquenilo, alquinilo, acilo, halo, hidroxi, -NH2, -NH(alquil), -N(alquil)2, -NH(cicloalquil), -N(alquil)(cicloalquil), -NH(heterocicloalquil), -NH(heteroaril), -NH-alquil-heterocicloalquilo, -NH-alquil-heteroarilo, -NH(aralquil),cicloalquilo, (cicloalquil)alquilo, arilo, aralquilo, aroilo, heterocicloalquilo, (heterocicloalquil)alquilo, heteroarilo, heteroaralquilo, heteroaroilo, nitro, ciano, guanadino, amidino, carboxi, sulfo, mercapto, alcoxi, cicloalquiloxi,(cicloalquil)alcoxi, ariloxi, arilalcoxi, heterocicloalquiloxi, (heterocicloalquil)alcoxi, heteroariloxi, heteroarilalcoxi, alquilsulfanilo, cicloalquilsulfanilo, (cicloalquil)alquilsulfanilo, arilsulfanilo, aralquilsulfanilo,heterocicloalquilsulfanilo, (heterocicloalquil)alquilsulfanilo, heteroarilsulfanilo, heteroarilalquilsulfanilo, alquilsulfinilo, alquilsulfonilo, aminocarbonilo, aminosulfonilo, alquilcarbonilamino, cicloalquilcarbonilamino,(cicloalquil)alquilcarbonilamino, arilcarbonilamino, aralquilcarbonilamino, (heterocicloalquil)carbonilamino, (heterocicloalquil)alquilcarbonilamino, heteroarilcarbonilamino, heteroaralquilcarbonilamino, alcoxicarbonilaminoalquilamino,(heteroaril)arilcarbonilaminoalquilamino, heteroaralquilcarbonilaminoalquilamino, (heteroaril)arilsulfonilaminoalquilcarbonilaminoalquilamino, arilsulfonilaminoalquilamino, alcoxicarbonilo, alquilcarboniloxi, urea, tiourea, sulfamoilo, sulfamida, ocarbamoilo; m es seleccionado de entre 0, 1, 2, 3, o 4; siempre que cuando m l 2, dos grupos R1 adyacentes pueden unirse entre sí para formar una porción cíclica opcionalmente sustituida de 4 a 8 miembros; n es seleccionado de entre 0, 1, 2, o 3;siempre que, cuando n l 2, dos grupos R2 adyacentes puedan unirse entre sí para formar una porción cíclica opcionalmente sustituida de 4 a 8 miembros; cada uno de Rx y Ry es independientemente seleccionado de entre H, alquilo, alquenilo, alquinilo,alcoxi, acilo, halo, hidroxi, amino, nitro, ciano, guanadino, amidino, carboxi, sulfo, mercapto, alquilsulfanilo, alquilsulfinilo, alquilsulfonilo, cicloalquilcarbonilo, (cicloalquil)alquilcarbonilo, aroilo, aralquilcarbonilo,heterocicloalquilcarbonilo, (heterocicloalquil)acilo, heteroaroilo, (heteroaril)acilo, aminocarbonilo, alquilcarbonilamino, (amino)aminocarbonilo, alquilsulfonilaminocarbonilo, alquilsulfonilamino, cicloalquilcarbonilamino, cicloalquilsulfonilamino,(cicloalquil)alquilcarbonilamino, (cicloalquil)alquilsulfonilamino, arilcarbonilamino, arilsulfonilamino, aralquilcarbonilamino, aralquilsulfonilamino, (heterocicloalquil)carbonilamino, (heterocicloalquil)sulfonilamino,(heterocicloalquil)alquilcarbonilamino, (heterocicloalquil)alquilsulfonilamino. heteroarilcarbonilamino, heteroarilsulfonilamino, heteroaralquilcarbonilamino, heteroaralquilsulfonilamino, alcoxicarbonilo, alquilcarboniloxi, urea, tiourea,sulfamoilo, sulfamida, carbamoilo, cicloalquilo, cicloalquiloxi, cicloalquilsulfanilo, (cicloalquil)alquilo, (cicloalquil)alcoxi, (cicloalquil)alquilsulfanilo, heterocicloalquilo, heterocicloalquiloxi, heterocicloalquilsulfanilo,(heterocicloalquil)alquilo, (heterocicloalquil)alcoxi, (heterocicloalquil)alquilsulfanilo, arilo, ariloxi, arilsulfanilo, aralquilo, aralquiloxi, aralquilsulfanilo, arilalquenilo, arilalquinilo, heteroarilo, heteroariloxi, heteroarilsulfanilo,heteroaralquilo, (heteroaril)alcoxi, o (heteroaril)alquilsulfanilo; o una sal farmacéuticamente aceptable o un N-óxido de los mismos.
ARP030103249A 2002-09-06 2003-09-08 Imidazolpiridinas y metodos para preparar y usarlas AR041206A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US40881202P 2002-09-06 2002-09-06

Publications (1)

Publication Number Publication Date
AR041206A1 true AR041206A1 (es) 2005-05-11

Family

ID=31978685

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030103249A AR041206A1 (es) 2002-09-06 2003-09-08 Imidazolpiridinas y metodos para preparar y usarlas

Country Status (20)

Country Link
US (1) US20060135517A1 (es)
EP (1) EP1546112A4 (es)
JP (1) JP2006502164A (es)
KR (1) KR20050035296A (es)
CN (1) CN1694871B (es)
AR (1) AR041206A1 (es)
AU (1) AU2003270318B2 (es)
BR (1) BR0314052A (es)
CA (1) CA2497968A1 (es)
EA (1) EA010426B1 (es)
GE (1) GEP20074165B (es)
MX (1) MXPA05002442A (es)
MY (1) MY139566A (es)
NO (1) NO20051493D0 (es)
NZ (1) NZ539068A (es)
PL (1) PL375691A1 (es)
RS (1) RS20050199A (es)
UA (1) UA80296C2 (es)
WO (1) WO2004021989A2 (es)
ZA (1) ZA200501853B (es)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8595001A1 (es) * 2003-03-04 2004-09-28 Pfizer Prod Inc Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf)
JP4931589B2 (ja) * 2004-07-02 2012-05-16 正明 松岡 ＴＧＦβ２を標的としたアルツハイマー病治療薬のスクリーニング法
US7718801B2 (en) 2004-08-31 2010-05-18 Banyu Pharmaceutical Co., Ltd. Substituted imidazole derivative
AU2005280168A1 (en) * 2004-08-31 2006-03-09 Biogen Idec Ma Inc. Pyrimidinylimidazoles as TGF-beta inhibitors
WO2006044509A2 (en) * 2004-10-15 2006-04-27 Biogen Idec Ma Inc. Methods of treating vascular injuries
US20080167314A1 (en) * 2004-12-28 2008-07-10 Osamu Uchikawa Condensed Imidazole Compound And Use Thereof
US7666880B2 (en) 2005-03-21 2010-02-23 S*Bio Pte Ltd. Imidazo[1,2-A]pyridine derivatives: preparation and pharmaceutical applications
AR056187A1 (es) * 2005-03-21 2007-09-26 S Bio Pte Ltd Derivados de imidazo[1,2-a)piridina: preparacion, composiciones farmaceuticas y uso para preparar medicamentos
US20070155738A1 (en) 2005-05-20 2007-07-05 Alantos Pharmaceuticals, Inc. Heterobicyclic metalloprotease inhibitors
JP2009507032A (ja) * 2005-09-02 2009-02-19 アボット・ラボラトリーズ 新規なイミダゾ系複素環
WO2007076086A2 (en) * 2005-12-22 2007-07-05 Biogen Idec Ma Inc Tricyclic spiro compounds useful as transforming growth factor modulators
DE102005061840A1 (de) * 2005-12-23 2007-06-28 Merck Patent Gmbh Triazolderivate
US7563797B2 (en) 2006-08-28 2009-07-21 Forest Laboratories Holding Limited Substituted imidazo(1,2-A)pyrimidines and imidazo(1,2-A) pyridines as cannabinoid receptor ligands
MX2009003518A (es) 2006-10-03 2009-08-25 Genzyme Corp Uso de antagonistas de tgf-beta para tratar a los infantes en riesgo de desarrollar displasia brocopulmonar.
US7977336B2 (en) 2006-12-28 2011-07-12 Banyu Pharmaceutical Co. Ltd Aminopyrimidine derivatives as PLK1 inhibitors
WO2008116064A2 (en) 2007-03-21 2008-09-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful for the treatment of proliferative, allergic, autoimmune or inflammatory diseases
WO2008133192A1 (ja) * 2007-04-19 2008-11-06 Takeda Pharmaceutical Company Limited 縮合イミダゾール化合物およびその用途
WO2010009166A1 (en) 2008-07-14 2010-01-21 Gilead Colorado, Inc. Oxindolyl inhibitor compounds
AU2009271003A1 (en) 2008-07-14 2010-01-21 Gilead Sciences, Inc. Imidazolylpyrimidine compounds as HDAC and/or CDK inhibitors
NZ602832A (en) 2008-07-14 2014-04-30 Gilead Sciences Inc Fused heterocyclic hdac inhibitor compounds
US8476430B2 (en) 2008-07-24 2013-07-02 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
BRPI0916713A2 (pt) 2008-07-28 2015-11-10 Gilead Science Inc compostos inibidores de histona desacetilase de cicloalquilideno e heterocicloalquilideno
US8759356B2 (en) * 2009-05-19 2014-06-24 Dow Agrosciences, Llc. Compounds and methods for controlling fungi
US8536180B2 (en) * 2009-05-27 2013-09-17 Abbvie Inc. Pyrimidine inhibitors of kinase activity
AU2010259042A1 (en) 2009-06-08 2011-12-15 Gilead Sciences, Inc. Cycloalkylcarbamate benzamide aniline HDAC inhibitor compounds
EP2440519A1 (en) 2009-06-08 2012-04-18 Gilead Sciences, Inc. Alkanoylamino benzamide aniline hdac inihibitor compounds
CA2778949C (en) 2009-10-30 2018-02-27 Janssen Pharmaceutica Nv Imidazo[1,2-b]pyridazine derivatives and their use as pde10 inhibitors
WO2011074658A1 (ja) 2009-12-18 2011-06-23 田辺三菱製薬株式会社 新規抗血小板薬
AR080754A1 (es) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
JP5959330B2 (ja) * 2011-06-17 2016-08-02 田辺三菱製薬株式会社 新規抗血小板薬
BR112013033375B1 (pt) 2011-06-27 2022-05-10 Janssen Pharmaceutica N.V Derivados de 1-aril-4-metil-[1,2,4]triazolo[4,3-a]quinoxa-lina, seu uso, composição farmacêutica que os compreende, processo de preparação dos mesmos, solução estéril e composto intermediário
WO2013014262A1 (en) 2011-07-27 2013-01-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing and treating myhre syndrome
MX2014004994A (es) 2011-10-26 2014-08-27 Seattle Children S Res Inst Cisteamina en el tratamiento de enfermedad fibrotica.
WO2014001314A1 (en) 2012-06-26 2014-01-03 Janssen Pharmaceutica Nv Combinations comprising pde 2 inhibitors such as 1-aryl-4-methyl- [1,2,4] triazolo [4,3-a] quinoxaline compounds and pde 10 inhibitors for use in the treatment of neurological or metabolic disorders
JP6174695B2 (ja) 2012-07-09 2017-08-02 ヤンセン ファーマシューティカ エヌ．ベー． ホスホジエステラーゼ１０酵素の阻害剤
EP2903647B1 (en) 2012-10-05 2020-01-01 Kadmon Corporation, LLC Human anti-vegfr-2/kdr antibodies
WO2014081906A2 (en) 2012-11-21 2014-05-30 Ptc Therapeutics, Inc. Substituted reverse pyrimidine bmi-1 inhibitors
DK2970890T3 (da) 2013-03-14 2020-05-04 Brigham & Womens Hospital Inc Sammensætninger og fremgangsmåder til opformering og dyrkning af epitelstamceller
US9776997B2 (en) * 2013-06-04 2017-10-03 Bayer Pharma Aktiengesellschaft 3-aryl-substituted imidazo[1,2-A]pyridines and their use
EP3039015B1 (en) 2013-08-30 2019-10-30 PTC Therapeutics, Inc. Substituted pyrimidine bmi-1 inhibitors
US10584115B2 (en) 2013-11-21 2020-03-10 Ptc Therapeutics, Inc. Substituted pyridine and pyrazine BMI-1 inhibitors
KR102421235B1 (ko) 2014-02-13 2022-07-15 인사이트 코포레이션 Lsd1 저해제로서 사이클로프로필아민
WO2015123437A1 (en) 2014-02-13 2015-08-20 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
CR20160395A (es) 2014-02-13 2016-12-20 Incyte Corp Ciclopropilaminas como inhibidores de lsd1
ES2672797T3 (es) 2014-02-13 2018-06-18 Incyte Corporation Ciclopropilaminas como inhibidores de LSD1
JP2017507140A (ja) 2014-02-19 2017-03-16 バイエル・ファルマ・アクティエンゲゼルシャフト ３−（ピリミジン−２−イル）イミダゾ［１，２−ａ］ピリジン
US9695180B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors
US9695167B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors
US9695168B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted imidazo[1,5-α]pyridines and imidazo[1,5-α]pyrazines as LSD1 inhibitors
US9758523B2 (en) 2014-07-10 2017-09-12 Incyte Corporation Triazolopyridines and triazolopyrazines as LSD1 inhibitors
US10568883B2 (en) 2014-09-03 2020-02-25 Massachusetts Institute Of Technology Compositions, systems, and methods for generating inner ear hair cells for treatment of hearing loss
US10292970B2 (en) 2014-12-02 2019-05-21 Bayer Pharma Aktiengesellschaft Heteroaryl-substituted imidazo[1,2-A]pyridines and their use
US11384350B2 (en) 2014-12-15 2022-07-12 The Regents Of The University Of California Cytotoxic molecules responsive to intracellular ligands for selective T cell mediated killing
EP3277689B1 (en) 2015-04-03 2019-09-04 Incyte Corporation Heterocyclic compounds as lsd1 inhibitors
BR112018002553A8 (pt) 2015-08-12 2023-01-24 Incyte Corp Sais de um inibidor de lsd1
EP3368571B1 (en) 2015-10-30 2022-12-07 The Regents of The University of California Transforming growth factor-beta-responsive polypeptides and their methods for use
EP3400286A1 (en) 2016-01-08 2018-11-14 Massachusetts Institute Of Technology Production of differentiated enteroendocrine cells and insulin producing cells
US11583593B2 (en) 2016-01-14 2023-02-21 Synthis Therapeutics, Inc. Antibody-ALK5 inhibitor conjugates and their uses
US11260130B2 (en) 2016-03-02 2022-03-01 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV
US10201540B2 (en) 2016-03-02 2019-02-12 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I
US10213511B2 (en) 2016-03-02 2019-02-26 Frequency Therapeutics, Inc. Thermoreversible compositions for administration of therapeutic agents
WO2017184934A1 (en) 2016-04-22 2017-10-26 Incyte Corporation Formulations of an lsd1 inhibitor
WO2018042385A2 (en) 2016-09-02 2018-03-08 The Regents Of The University Of California Methods and compositions involving interleukin-6 receptor alpha-binding single chain variable fragments
MX2019007890A (es) 2016-12-30 2020-01-20 Frequency Therapeutics Inc Compuestos de 1h-pirrol-2,5-diona y metodos de uso de los mismos para inducir la auto-renovacion de celulas madre/progenitoras de soporte.
WO2018141002A2 (en) * 2017-02-01 2018-08-09 University Of South Australia DERIVATIVES OF N-CYCLOALKYL/HETEROCYCLOALKYL-4-(IMIDAZO [1,2-a]PYRIDINE)PYRIMIDIN-2-AMINE AS THERAPEUTIC AGENTS
MX2020003341A (es) * 2017-10-18 2020-09-17 Jubilant Epipad LLC Compuestos de imidazo-piridina como inhibidores de pad.
EP3700522A4 (en) * 2017-10-26 2021-08-11 Southern Research Institute OXADIAZOLES AND THIADIAZOLES AS TGF-BETA INHIBITORS
AU2019212969A1 (en) * 2018-01-29 2020-08-13 Merck Patent Gmbh GCN2 inhibitors and uses thereof
JP2021518413A (ja) 2018-03-20 2021-08-02 アイカーン スクール オブ メディシン アット マウント サイナイ キナーゼ阻害剤化合物及び組成物ならびに使用方法
EP3820467A4 (en) * 2018-07-09 2022-05-04 Synthis Therapeutics, Inc. ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES
EP3827010A4 (en) 2018-07-23 2022-03-16 Brise Pharmaceuticals Co., Ltd. BISPHOSPHONATE-DRUG CONJUGATES
CA3109647A1 (en) 2018-08-17 2020-02-20 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by upregulating jag-1
WO2020037326A1 (en) 2018-08-17 2020-02-20 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by downregulating foxo
US10968200B2 (en) 2018-08-31 2021-04-06 Incyte Corporation Salts of an LSD1 inhibitor and processes for preparing the same
WO2020142485A1 (en) 2018-12-31 2020-07-09 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
EP3947737A2 (en) 2019-04-02 2022-02-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting and preventing cancer in patients having premalignant lesions
WO2020256721A1 (en) 2019-06-19 2020-12-24 Synthis, Llc Antib0dy-alk5 inhibitor conjugates and their uses
WO2023125541A1 (zh) * 2021-12-27 2023-07-06 浙江光昊光电科技有限公司 一种有机电子器件

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3940486A (en) * 1971-05-10 1976-02-24 Ciba-Geigy Corporation Imidazole derivatives in the treatment of pain
US4302464A (en) * 1980-10-16 1981-11-24 Pfizer Inc. Imidazolylpyridine therapeutic agents
US4686231A (en) * 1985-12-12 1987-08-11 Smithkline Beckman Corporation Inhibition of 5-lipoxygenase products
US5656644A (en) * 1994-07-20 1997-08-12 Smithkline Beecham Corporation Pyridyl imidazoles
US5593992A (en) * 1993-07-16 1997-01-14 Smithkline Beecham Corporation Compounds
US5670527A (en) * 1993-07-16 1997-09-23 Smithkline Beecham Corporation Pyridyl imidazole compounds and compositions
US5593991A (en) * 1993-07-16 1997-01-14 Adams; Jerry L. Imidazole compounds, use and process of making
GB9423460D0 (en) * 1994-11-21 1995-01-11 Merck Sharp & Dohme Therapeutic agents
US5514505A (en) * 1995-05-15 1996-05-07 Xerox Corporation Method for obtaining improved image contrast in migration imaging members
US5739143A (en) * 1995-06-07 1998-04-14 Smithkline Beecham Corporation Imidazole compounds and compositions
IL118544A (en) * 1995-06-07 2001-08-08 Smithkline Beecham Corp History of imidazole, the process for their preparation and the pharmaceutical preparations containing them
US5792778A (en) * 1995-08-10 1998-08-11 Merck & Co., Inc. 2-substituted aryl pyrroles, compositions containing such compounds and methods of use
US5837719A (en) * 1995-08-10 1998-11-17 Merck & Co., Inc. 2,5-substituted aryl pyrroles, compositions containing such compounds and methods of use
US5717100A (en) * 1995-10-06 1998-02-10 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
US5756499A (en) * 1996-01-11 1998-05-26 Smithkline Beecham Corporation Substituted imidazole compounds
ZA97175B (en) * 1996-01-11 1997-11-04 Smithkline Beecham Corp Novel substituted imidazole compounds.
WO2000026216A1 (en) * 1998-11-03 2000-05-11 Glaxo Group Limited Pyrazolopyridine derivatives as selective cox-2 inhibitors
CO5271680A1 (es) * 2000-02-21 2003-04-30 Smithkline Beecham Corp Compuestos
JP4290858B2 (ja) * 2000-06-12 2009-07-08 富士フイルム株式会社 有機電界発光素子
US20040039198A1 (en) * 2000-11-16 2004-02-26 Bender Paul E. Compounds
WO2004013135A1 (en) * 2002-07-31 2004-02-12 Smithkline Beecham Corporation 2-phenylpyridin-4-yl derivatives as alk5 inhibitors
GB0217783D0 (en) * 2002-07-31 2002-09-11 Glaxo Group Ltd Compounds
PA8595001A1 (es) * 2003-03-04 2004-09-28 Pfizer Prod Inc Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf)

Also Published As

Publication number Publication date
CN1694871B (zh) 2010-06-16
US20060135517A1 (en) 2006-06-22
WO2004021989A2 (en) 2004-03-18
WO2004021989A3 (en) 2004-09-23
NO20051493L (no) 2005-03-21
BR0314052A (pt) 2005-07-05
EP1546112A2 (en) 2005-06-29
JP2006502164A (ja) 2006-01-19
KR20050035296A (ko) 2005-04-15
EP1546112A4 (en) 2006-06-07
EA200500453A1 (ru) 2005-10-27
CN1694871A (zh) 2005-11-09
AU2003270318A1 (en) 2004-03-29
CA2497968A1 (en) 2004-03-18
NO20051493D0 (no) 2005-03-21
EA010426B1 (ru) 2008-08-29
NZ539068A (en) 2006-10-27
RS20050199A (en) 2007-08-03
AU2003270318B2 (en) 2010-01-14
ZA200501853B (en) 2005-11-30
UA80296C2 (en) 2007-09-10
PL375691A1 (en) 2005-12-12
GEP20074165B (en) 2007-07-25
MY139566A (en) 2009-10-30
MXPA05002442A (es) 2005-09-30

Similar Documents

Publication Publication Date Title
AR041206A1 (es) Imidazolpiridinas y metodos para preparar y usarlas
AR041207A1 (es) Pirazolo piridinas
AR039241A1 (es) Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
AR062196A1 (es) Imidazo[4,5-b]pirazinas e imidazo[4,5-b]quinoxalinas, composiciones y metodos
GR3032151T3 (en) Sulphonamide derivatives as aspartyl protease inhibitors
PE20070124A1 (es) Derivados de heteroaril para tratar virus
AR029887A1 (es) Compuestos para el tratamiento de la isquemia, su uso en la fabricacion de medicamentos y composiciones que los contienen
AR042659A1 (es) Derivados de 4-5 diariltiazoles como ligandos de cb-1
AR051587A1 (es) Metodos para tratar lesiones vascularesy dispositivo implantable
AR050622A1 (es) Derivados de pirimidinilpirazoles como inhibidores de la via de senalizacion por tgfbeta y composiciones farmaceuticas que los contienen.
AR036492A1 (es) Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3, composiciones farmaceuticas y el uso de dichos inhibidores para la elaboracion de un medicamento para el tratamiento de enfermedades androgeno dependientes
BR0305259A (pt) Inibidores de hcv ns5b polimerase
ES2160046A1 (es) Derivados pentapeptidicos.
BR0305426A (pt) Compostos inibidores de ns5b polimerase de hcv, bem como composição farmacêutica compreendendo os mesmos
RS20050432A (en) Novel aromatic fluoroglycoside derivatives,pharmaceutical products containing said compounds and the use thereof
PE20050015A1 (es) Derivados (3-oxo-morfolin-4-il)-fenilamida como inhibidores de factores de coagulacion y compuestos intermediarios en su preparacion
RU2006143842A (ru) Новые замещенные тиофенкарбоксамиды, их получение и их применение в качестве лекарственных средств
CY1112042T1 (el) Ιικοι αναστολεις
RU95122612A (ru) 4-аминопиридины, способ их получения, содержащие эти соединения лекарственные средства
AR047671A1 (es) Compuestos de arilnitrona 2-sustituidos y 4-sustituidos
BRPI0519759A2 (pt) composiÇÕes farmacÊuticas
AR014868A1 (es) UN COMPUESTO DERIVADO DE N,N ( SUSTITUIDO) FENIL (ARILO O HETEROARILO) PROPANAMINA, UNA COMPOSICIoN FARMACÉUTICA, USO DE DICHO COMPUESTO Y UN MÉTODO PARA PREPARARLO.
BR0002518A (pt) Derivados de 4-arilpiperidina para o tratamento de prurido
AR019427A1 (es) Compuestos heterociclicos como inhibidores de enzimas de rotamasa, procedimiento para su preparacion, su uso para la preparacion de medicamentos, composiciones farmaceuticas y compuestos intermediarios utiles para su preparacion
BR0002515A (pt) Derivados de 4-arilpiperidina para o tratamento do prurido

Legal Events

Date Code Title Description
FA Abandonment or withdrawal
FB Suspension of granting procedure